Trial site
Wsd Medi Clinical Sp. z o.o.
Warsaw, 02-786, PolandEU-13 widening countryNot linked to an institution yet
- 17running trials
- 4closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Phase
- Phase 213 trials
- Phase 37 trials
- Phase 2/31 trial
- Status
- Active, not recruiting8 trials
- Recruiting8 trials
- Completed4 trials
- Not yet recruiting1 trial
- Lead sponsor
- Janssen Research & Development, LLC3 trials
- AbbVie2 trials
- MoonLake Immunotherapeutics AG2 trials
- Spyre Therapeutics, Inc.2 trials
- Agomab Spain S.L.U.1 trial
- and 11 more
Running trials
Enrolling by invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073· Phase 2· Eli Lilly and Company· Source
Recruiting
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study
2025-522338-30-00· Phase 2· Eli Lilly & Co.· Source
Not yet recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336· Phase 2· Genentech, Inc.· Source
Completed
A Study With CIT-013 in RA Patients
NCT06567470· Phase 2· Citryll BV· Source
Active, not recruiting
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744· Phase 3· AbbVie· Source
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395· Phase 2· Spyre Therapeutics, Inc.· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.
2024-516219-25-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· Phase 3· Pfizer· Source
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source
Active, not recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967· Phase 3· AbbVie· Source
Active, not recruiting
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05668013· Phase 2· Teva Branded Pharmaceutical Products R&D LLC· Source
Active, not recruiting
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843· Phase 2· Sanofi· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error